Medigene Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Medigene has a total shareholder equity of €19.7M and total debt of €0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are €28.8M and €9.2M respectively.

Belangrijke informatie

Verhouding schuld/eigen vermogen

€0

Schuld

Rente dekkingsratio	n/a
Contant	€14.02m
Aandelen	€19.66m
Totaal verplichtingen	€9.15m
Totaal activa	€28.81m

Recente financiële gezondheidsupdates

Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation

Jan 03

We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely

Mar 24

Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

Nov 29

We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate

Mar 29

Recent updates

Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation

Jan 03

The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business

Aug 12

Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%

Aug 10

We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely

Mar 24

Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

Nov 29

This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO

Jun 17

We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate

Mar 29

How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 16

How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?

Dec 23

Analyse van de financiële positie

Kortlopende schulden: MDG1's short term assets (€15.6M) exceed its short term liabilities (€6.5M).

Langlopende schulden: MDG1's short term assets (€15.6M) exceed its long term liabilities (€2.6M).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: MDG1 is debt free.

Schuld verminderen: MDG1 had no debt 5 years ago.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: MDG1 has less than a year of cash runway based on its current free cash flow.

Voorspelling contante baan: MDG1 has less than a year of cash runway if free cash flow continues to grow at historical rates of 10.2% each year.

Medigene Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation

We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate

Recent updates

Medigene AG Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

New minor risk - Share price stability

Consensus EPS estimates fall by 18%

Second quarter 2024 earnings released: €0.15 loss per share (vs €0.17 loss in 2Q 2023)

Medigene AG Reaffirms Revenue Guidance for the Year 2024

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

New major risk - Financial position

Medigene AG to Report First Half, 2024 Results on Aug 14, 2024

Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness

New minor risk - Shareholder dilution

Medigene AG, Annual General Meeting, Jun 24, 2024

Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS

Medigene Ag Maintains Earnings Guidance for 2024

Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein

Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process

Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024

Medigene AG Secures European Patent for Its iM-TCR Technology

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Medigene Ag Provides Earnings Guidance for 2024

Medigene AG to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Financial data availability

Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors

Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation

Medigene AG Maintains Financial Guidance for the Fiscal Year 2023

Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing

Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023

Medigene AG Provides Revenue Guidance for 2023

New major risk - Financial position

Second quarter 2023 earnings released: €0.17 loss per share (vs €0.097 loss in 2Q 2022)

New minor risk - Share price stability

Full year 2022 earnings released: €0.34 loss per share (vs €0.41 loss in FY 2021)

Medigene AG to Report Q3, 2023 Results on Oct 26, 2023

Price target decreased to €3.90

Medigene AG Maintains Revenue Guidance for the Fiscal Year 2022

The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business

Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%

Price target decreased to €5.95

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

Medigene AG Announces Publication Details Augmentation of PRAME-Specific TCR-4 by PD1-41BB Switch Receptor

Medigene AG to Report Q3, 2022 Results on Nov 02, 2022

We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely

No longer forecast to breakeven

Medigene AG Reports Preliminary Efficacy and Immune Monitoring Data of Phase I of Phase I/II MDG1011 Trial in Blood Cancers

Medigene AG Achieves Positive Preliminary Results in Phase I of Phase I/II Trial of TCR-T Therapy MDG1011 in Blood Cancers

Consensus revenue estimates increase to €10.5m

Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

Price target decreased to €6.73

Medigene's PD1-41BB Switch Receptor Improves TCR-T Cell Functionality Against Solid Tumors

Price target decreased to €6.80

Medigene Confirms Revenue Guidance for 2021

This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO

Medigene AG Provides Earnings Guidance for the Year 2021

Consensus forecasts updated

Advisor has left the company

We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate

Full year 2020 earnings released: €1.18 loss per share (vs €0.81 loss in FY 2019)

Medigene AG Announces Executive Changes

Medigene AG to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Price target raised to €8.51

How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?

Medigene AG Presents Further Encouraging Results from the Follow-Up of Acute Myeloid Leukemia Patients

Medigene AG Announces Discontinuation of MDG1021 Development Program

New 90-day high: €3.92

How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?

Price target lowered to €6.87

Medigene AG Announces Board Changes

Medigene AG, Annual General Meeting, Jun 24, 2021

Medigene AG Provides Update on MDG1011 Phase I/II clinical trial

New 90-day low - €4.43

Earnings released

Analyse van de financiële positie